Recruiting

Vertebroplasty with Radiation

Sponsor:

Ohio State University Comprehensive Cancer Center

Code:

NCT05178472

Conditions

Hematopoietic and Lymphoid Cell Neoplasm

Malignant Solid Neoplasm

Metastatic Malignant Neoplasm in the Spine

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Immunotherapy

Stereotactic Radiosurgery

Vertebroplasty

Study Details

Brief summary:

This clinical trial studies the side effects of stereotactic radiosurgery and how well it works with or without vertebroplasty, separation surgery, or immunotherapy in patients with cancer that is radiation resistant and has spread to the spine (spinal metastases). Spinal metastases are rapidly progressive, have poor prognosis, are extremely difficult to treat, and can effect patient quality of life and overall health. Immunotherapy is a type of standard of care therapy to boost or restore the ability of the immune system to fight cancer. Stereotactic radiosurgery is a type of external radiation therapy that uses special equipment to position the patient and precisely give a single large dose of radiation to a tumor. A vertebroplasty is a procedure used to repair a bone in the spine that has a break caused by cancer, osteoporosis, or trauma. The purpose of this trial is to test different combinations of immunotherapy, stereotactic radiosurgery, and surgery to improve overall survival and quality of life in patients with spinal metastases.

Conditions

Hematopoietic and Lymphoid Cell Neoplasm

Malignant Solid Neoplasm

Metastatic Malignant Neoplasm in the Spine

Study ID

NCT05178472

Start date

Mar 27, 2023

Status verified date

Apr, 2026

Completion date

Dec 31, 2026

Anticipated

Primary completion date

Dec 31, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • At least 18 years of age and older with indeterminate Spine Metastasis.
  • All patients with histology that requires stereotactic RT as a part of their treatment.
  • Eastern Cooperative Oncology Group (ECOG) performance status =< 2
  • Disease visualized by CT or MRI
  • Prior radiation therapy will be allowed at the discretion of the Radiation Oncologist based on current standard operating procedures.
  • Tumor tissue from the core biopsy or resected site of disease will be collected, if available for biomarker analyses.
  • Four or less consecutive spinal segments involved by tumor. Or four or less separate spinal tumor targets with a minimum of one vertebral body separation
  • Patient is able (i.e. sufficiently fluent) and willing to complete the quality of life questionnaire in either English or Spanish. The baseline assessment must be completed within required timelines. Inability (illiteracy in English or Spanish, loss of sight, or other equivalent reason) to complete the questionnaires will not make the patient ineligible for the study. However, ability but unwillingness to complete the questionnaires will make the patient ineligible

Exclusion Criteria:

  • Patients < 18 years of age
  • Inability to get a standard MRI or CT myelogram for radiation treatment target delineation
  • Patients with prior radiation to the spinal segment to be treated may be included if the radiation dose can be delivered safely, per the treating radiation oncologist.
  • Patients with symptomatic spinal cord compression requiring emergent surgery
  • Pregnant or lactating women
  • Systemic therapy or immunosuppressive medications, excluding immunotherapy, within 3-14 days of radiation treatment, at the discretion of the treating radiation oncologist .
  • Patients with stable or unstable lesions based on SINS criteria

Study Design

Enrollment

200 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Supportive Care

Interventions and Outcome Measures

Arms

experimental: Arm I (vertebroplasty)

Patients undergo vertebroplasty and, 2-4 weeks later, undergo SRS over 1-3 fractions depending upon the number of affected vertebral bodies. Patients also receive standard of care immunotherapy IV every 2 weeks for up to 6 months in the absence of disease progression or unacceptable toxicity.

active comparator: Arm II (no vertebroplasty)

Patients receive standard of care immunotherapy IV every 2 weeks for up to 6 months and undergo SRS over 1-3 fractions depending upon the number of affected vertebral bodies in the absence of disease progression or unacceptable toxicity.

Interventions

Immunotherapy

Receive SOC immunotherapy

Stereotactic Radiosurgery

Undergo SRS

Vertebroplasty

Undergo vertebroplasty

Primary outcome measure

  • Vertebral compression fracture (VCF) rate [ Time Frame: At 6 months ]
  • Local control [ Time Frame: At 6 months ]

Central Contacts and Locations

Central contacts

The Ohio State University Comprehensive Cancer Center

800-293-5066OSUCCCClinicaltrials@osumc.edu

Locations

Ohio State University Comprehensive Cancer Center

Recruiting

Columbus, Ohio, United States, 43210

Contacts

Dukagjin M. Blakaj

Dukagjin.blakaj@osumc.edu

Principal Investigator:

Dukagjin M. Blakaj

More Information

Sponsor

Ohio State University Comprehensive Cancer Center

Last update posted

Apr 9, 2026

Last verified

Apr, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by Ohio State University Comprehensive Cancer Center on 2026-04-09.